Anthem adds Intersect ENT’s Sinuva implant to formulary

Anthem this month added Intersect ENT‘s (NSDQ:XENT) Sinuva steroid-releasing implant to its updated formulary as a Tier 3 product, according to a note from Leerink analysts.

The product is designated on Anthem’s formulary as “LD” – limited distribution – and is only available to certain pharmacies or wholesalers. Intersect ENT launched the product in the U.S. in April this year.

Get the full story at our sister site, Drug Delivery Business News.

The post Anthem adds Intersect ENT’s Sinuva implant to formulary appeared first on MassDevice.

from MassDevice https://ift.tt/2y7dRvn